ONTOLOGY REPORT - ANNOTATIONS
| Term: | dexamethasone |
|
| Accession: | CHEBI:41879
|
browse the term
|
| Definition: | A fluorinated steroid that has formula C22H29FO5. |
| Synonyms: | exact_synonym: | 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione |
| | related_synonym: | 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 9alpha-Fluoro-16alpha-methylprednisolone; C22H29FO5; Decadron; InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1; InChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N; [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C; dexametasona; dexamethasonum |
| | alt_id: | CHEBI:41873; CHEBI:4461 |
| | xref_casrn: | 50-02-2 |
| | xref: | Beilstein:2066652 "Beilstein Registry Number"; ChEMBL:465281 "ChEMBL COMPOUND"; ChemIDplus:50-02-2 "CAS Registry Number"; DrugBank:DB01234 "DrugBank"; KEGG DRUG:D00292 "KEGG DRUG" |
| | xref_mesh: | MESH:D003907 |
| | xref: | Patent:DE1113690 "Patent"; Patent:GB869511 "Patent"; Patent:US3007923 "Patent"; Wikipedia:Dexamethasone "Wikipedia" |
|
|
dexamethasone
|
| G |
A2m |
alpha-2-macroglobulin |
|
decreases expression |
EXP |
4 |
158,103,711 |
158,153,423 |
RGD:6480464 |
CTD |
| G |
Abca1 |
ATP-binding cassette, subfamily A (ABC1), member 1 |
|
increases expression |
EXP |
5 |
70,493,357 |
70,583,729 |
RGD:6480464 |
CTD |
| G |
Abca1 |
ATP-binding cassette, subfamily A (ABC1), member 1 |
|
multiple interactions |
ISO |
5 |
70,493,357 |
70,583,729 |
RGD:6480464 |
CTD |
| G |
Abca1 |
ATP-binding cassette, subfamily A (ABC1), member 1 |
|
multiple interactions |
EXP |
5 |
70,493,357 |
70,583,729 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
multiple interactions |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
increases expression |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
increases expression |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb4 |
ATP-binding cassette, subfamily B (MDR/TAP), member 4 |
|
increases expression |
EXP |
4 |
21,946,274 |
22,004,328 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
EXP |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
multiple interactions |
ISO |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
increases activity |
ISO |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
increases expression |
ISO |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
affects expression |
EXP |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
decreases expression |
EXP |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
multiple interactions |
EXP |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
increases expression |
EXP |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc6 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 6 |
|
affects expression |
EXP |
1 |
96,448,588 |
96,524,655 |
RGD:6480464 |
CTD |
| G |
Abcc6 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 6 |
|
decreases expression |
EXP |
1 |
96,448,588 |
96,524,655 |
RGD:6480464 |
CTD |
| G |
Abcg2 |
ATP-binding cassette, subfamily G (WHITE), member 2 |
|
multiple interactions |
ISO |
4 |
87,502,584 |
87,560,017 |
RGD:6480464 |
CTD |
| G |
Acadm |
acyl-CoA dehydrogenase, C-4 to C-12 straight chain |
|
decreases expression |
EXP |
2 |
251,866,645 |
251,890,729 |
RGD:6480464 |
CTD |
| G |
Acan |
aggrecan |
|
multiple interactions |
ISO |
1 |
134,787,341 |
134,848,992 |
RGD:6480464 |
CTD |
| G |
Acan |
aggrecan |
|
increases expression |
ISO |
1 |
134,787,341 |
134,848,992 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
increases expression |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
multiple interactions |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Acly |
ATP citrate lyase |
|
decreases expression |
EXP |
10 |
89,420,934 |
89,471,398 |
RGD:6480464 |
CTD |
| G |
Aco2 |
aconitase 2, mitochondrial |
|
decreases expression |
EXP |
7 |
120,223,788 |
120,266,944 |
RGD:6480464 |
CTD |
| G |
Aco2 |
aconitase 2, mitochondrial |
|
multiple interactions |
EXP |
7 |
120,223,788 |
120,266,944 |
RGD:6480464 |
CTD |
| G |
Acot7 |
acyl-CoA thioesterase 7 |
|
decreases expression |
EXP |
5 |
169,409,306 |
169,501,907 |
RGD:6480464 |
CTD |
| G |
Acox1 |
acyl-CoA oxidase 1, palmitoyl |
|
decreases expression |
EXP |
10 |
106,281,977 |
106,319,382 |
RGD:6480464 |
CTD |
| G |
Acp5 |
acid phosphatase 5, tartrate resistant |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
|
multiple interactions |
ISO |
16 |
49,036,892 |
49,081,416 |
RGD:6480464 |
CTD |
| G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
|
decreases expression |
EXP |
16 |
49,036,892 |
49,081,416 |
RGD:6480464 |
CTD |
| G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
|
multiple interactions |
ISO |
X |
36,168,547 |
36,232,162 |
RGD:6480464 |
CTD |
| G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
|
increases expression |
EXP |
X |
36,168,547 |
36,232,162 |
RGD:6480464 |
CTD |
| G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
|
multiple interactions |
EXP |
X |
36,168,547 |
36,232,162 |
RGD:6480464 |
CTD |
| G |
Actb |
actin, beta |
|
multiple interactions |
ISO |
12 |
12,047,070 |
12,050,040 |
RGD:6480464 |
CTD |
| G |
Actc1 |
actin, alpha, cardiac muscle 1 |
|
multiple interactions |
ISO |
3 |
99,901,022 |
99,906,558 |
RGD:6480464 |
CTD |
| G |
Actg2 |
actin, gamma 2, smooth muscle, enteric |
|
multiple interactions |
ISO |
4 |
117,732,482 |
117,747,006 |
RGD:6480464 |
CTD |
| G |
Adam12 |
ADAM metallopeptidase domain 12 |
|
multiple interactions |
ISO |
1 |
193,384,457 |
193,650,892 |
RGD:6480464 |
CTD |
| G |
Adam17 |
ADAM metallopeptidase domain 17 |
|
decreases expression |
EXP |
6 |
41,882,432 |
41,930,755 |
RGD:6480464 |
CTD |
| G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
multiple interactions |
ISO |
11 |
25,434,262 |
25,443,144 |
RGD:6480464 |
CTD |
| G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
|
increases expression |
EXP |
2 |
235,799,396 |
235,811,584 |
RGD:6480464 |
CTD |
| G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
|
multiple interactions |
EXP |
2 |
235,799,396 |
235,811,584 |
RGD:6480464 |
CTD |
| G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
|
multiple interactions |
ISO |
11 |
79,908,291 |
79,911,065 |
RGD:6480464 |
CTD |
| G |
Adm |
adrenomedullin |
|
multiple interactions |
ISO |
1 |
168,380,255 |
168,382,426 |
RGD:6480464 |
CTD |
| G |
Adora3 |
adenosine A3 receptor |
|
increases expression |
EXP |
2 |
201,157,782 |
201,161,425 |
RGD:6480464 |
CTD |
| G |
Adra1b |
adrenoceptor alpha 1B |
|
increases expression |
ISO |
10 |
28,889,092 |
28,946,889 |
RGD:6480464 |
CTD |
| G |
Adra1d |
adrenoceptor alpha 1D |
|
increases expression |
ISO |
3 |
119,279,974 |
119,295,985 |
RGD:6480464 |
CTD |
| G |
Adrb2 |
adrenoceptor beta 2, surface |
|
increases expression |
EXP |
18 |
58,174,958 |
58,177,000 |
RGD:6480464 |
CTD |
| G |
Adrb2 |
adrenoceptor beta 2, surface |
|
multiple interactions |
EXP |
18 |
58,174,958 |
58,177,000 |
RGD:6480464 |
CTD |
| G |
Adrb2 |
adrenoceptor beta 2, surface |
|
multiple interactions |
ISO |
18 |
58,174,958 |
58,177,000 |
RGD:6480464 |
CTD |
| G |
Adrb3 |
adrenoceptor beta 3 |
|
decreases expression |
ISO |
16 |
69,163,620 |
69,166,384 |
RGD:6480464 |
CTD |
| G |
Agr2 |
anterior gradient 2 homolog (Xenopus laevis) |
|
multiple interactions |
ISO |
6 |
54,695,633 |
54,716,858 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
increases expression |
ISO |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
decreases expression |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
decreases expression |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
increases expression |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
EXP |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahsg |
alpha-2-HS-glycoprotein |
|
increases response to substance |
ISO |
11 |
80,330,615 |
80,336,658 |
RGD:6480464 |
CTD |
| G |
Aifm1 |
apoptosis-inducing factor, mitochondrion-associated 1 |
|
multiple interactions |
ISO |
X |
134,868,878 |
134,908,166 |
RGD:6480464 |
CTD |
| G |
Akap12 |
A kinase (PRKA) anchor protein 12 |
|
multiple interactions |
ISO |
1 |
34,979,039 |
35,068,763 |
RGD:6480464 |
CTD |
| G |
Akap7 |
A kinase (PRKA) anchor protein 7 |
|
multiple interactions |
ISO |
1 |
20,573,215 |
20,704,564 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases phosphorylation |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases phosphorylation |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
multiple interactions |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
multiple interactions |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
increases expression |
EXP |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
increases secretion |
EXP |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
|
affects expression |
EXP |
1 |
223,731,675 |
223,773,285 |
RGD:6480464 |
CTD |
| G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
|
affects expression |
EXP |
5 |
62,311,268 |
62,316,276 |
RGD:6480464 |
CTD |
| G |
Aldoa |
aldolase A, fructose-bisphosphate |
|
increases expression |
EXP |
1 |
185,970,658 |
185,974,615 |
RGD:6480464 |
CTD |
| G |
Alox5 |
arachidonate 5-lipoxygenase |
|
multiple interactions |
EXP |
4 |
152,610,283 |
152,657,891 |
RGD:6480464 |
CTD |
| G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
|
multiple interactions |
ISO |
5 |
156,501,739 |
156,558,727 |
RGD:6480464 |
CTD |
| G |
Ampd3 |
adenosine monophosphate deaminase 3 |
|
increases expression |
EXP |
1 |
168,519,462 |
168,568,291 |
RGD:6480464 |
CTD |
| G |
Ampd3 |
adenosine monophosphate deaminase 3 |
|
multiple interactions |
EXP |
1 |
168,519,462 |
168,568,291 |
RGD:6480464 |
CTD |
| G |
Amy1a |
amylase, alpha 1A (salivary) |
|
increases expression |
ISO |
2 |
209,548,721 |
209,563,532 |
RGD:6480464 |
CTD |
| G |
Angpt1 |
angiopoietin 1 |
|
multiple interactions |
ISO |
7 |
78,195,504 |
78,451,471 |
RGD:6480464 |
CTD |
| G |
Angptl4 |
angiopoietin-like 4 |
|
increases expression |
ISO |
7 |
16,261,623 |
16,267,852 |
RGD:6480464 |
CTD |
| G |
Angptl4 |
angiopoietin-like 4 |
|
affects response to substance |
ISO |
7 |
16,261,623 |
16,267,852 |
RGD:6480464 |
CTD |
| G |
Angptl4 |
angiopoietin-like 4 |
|
multiple interactions |
ISO |
7 |
16,261,623 |
16,267,852 |
RGD:6480464 |
CTD |
| G |
Angptl4 |
angiopoietin-like 4 |
|
increases expression |
EXP |
7 |
16,261,623 |
16,267,852 |
RGD:6480464 |
CTD |
| G |
Angptl4 |
angiopoietin-like 4 |
|
multiple interactions |
EXP |
7 |
16,261,623 |
16,267,852 |
RGD:6480464 |
CTD |
| G |
Ank1 |
ankyrin 1, erythrocytic |
|
decreases expression |
EXP |
16 |
73,333,564 |
73,437,926 |
RGD:6480464 |
CTD |
| G |
Ank1 |
ankyrin 1, erythrocytic |
|
multiple interactions |
EXP |
16 |
73,333,564 |
73,437,926 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
multiple interactions |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
multiple interactions |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
increases expression |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
increases localization |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
increases phosphorylation |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
affects response to substance |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
multiple interactions |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
affects response to substance |
EXP |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa3 |
annexin A3 |
|
multiple interactions |
ISO |
14 |
14,245,112 |
14,297,100 |
RGD:6480464 |
CTD |
| G |
Anxa6 |
annexin A6 |
|
multiple interactions |
ISO |
10 |
40,383,975 |
40,439,683 |
RGD:6480464 |
CTD |
| G |
Anxa8 |
annexin A8 |
|
multiple interactions |
ISO |
16 |
9,715,644 |
9,730,584 |
RGD:6480464 |
CTD |
| G |
Aox1 |
aldehyde oxidase 1 |
|
multiple interactions |
EXP |
9 |
56,693,698 |
56,774,115 |
RGD:6480464 |
CTD |
| G |
Aox1 |
aldehyde oxidase 1 |
|
increases expression |
EXP |
9 |
56,693,698 |
56,774,115 |
RGD:6480464 |
CTD |
| G |
Apcdd1 |
adenomatosis polyposis coli down-regulated 1 |
|
multiple interactions |
ISO |
18 |
59,088,709 |
59,091,205 |
RGD:6480464 |
CTD |
| G |
Apln |
apelin |
|
decreases expression |
EXP |
X |
134,387,285 |
134,396,762 |
RGD:6480464 |
CTD |
| G |
Apln |
apelin |
|
multiple interactions |
EXP |
X |
134,387,285 |
134,396,762 |
RGD:6480464 |
CTD |
| G |
Apoa1 |
apolipoprotein A-I |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Apoa4 |
apolipoprotein A-IV |
|
affects expression |
EXP |
8 |
49,233,142 |
49,233,431 |
RGD:6480464 |
CTD |
| G |
Apob |
apolipoprotein B |
|
increases expression |
EXP |
6 |
31,508,060 |
31,548,083 |
RGD:6480464 |
CTD |
| G |
Apoc3 |
apolipoprotein C-III |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Apoc3 |
apolipoprotein C-III |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Apoc3 |
apolipoprotein C-III |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Apoc3 |
apolipoprotein C-III |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Aqp7 |
aquaporin 7 |
|
increases expression |
EXP |
5 |
58,433,731 |
58,447,853 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
decreases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Araf |
v-raf murine sarcoma 3611 viral oncogene homolog |
|
multiple interactions |
ISO |
X |
12,556,904 |
12,568,583 |
RGD:6480464 |
CTD |
| G |
Areg |
amphiregulin |
|
decreases expression |
EXP |
14 |
18,466,313 |
18,475,571 |
RGD:6480464 |
CTD |
| G |
Arg2 |
arginase type II |
|
increases expression |
EXP |
6 |
101,901,653 |
101,928,282 |
RGD:6480464 |
CTD |
| G |
Arg2 |
arginase type II |
|
multiple interactions |
EXP |
6 |
101,901,653 |
101,928,282 |
RGD:6480464 |
CTD |
| G |
Arhgap10 |
Rho GTPase activating protein 10 |
|
increases expression |
ISO |
19 |
32,261,771 |
32,521,913 |
RGD:6480464 |
CTD |
| G |
Arhgap30 |
Rho GTPase activating protein 30 |
|
increases expression |
ISO |
13 |
87,295,074 |
87,335,018 |
RGD:6480464 |
CTD |
| G |
Arhgap5 |
Rho GTPase activating protein 5 |
|
multiple interactions |
ISO |
6 |
72,685,231 |
72,693,052 |
RGD:6480464 |
CTD |
| G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
|
increases expression |
EXP |
2 |
190,333,978 |
190,391,015 |
RGD:6480464 |
CTD |
| G |
Art1 |
ADP-ribosyltransferase 1 |
|
multiple interactions |
EXP |
1 |
159,586,246 |
159,590,797 |
RGD:6480464 |
CTD |
| G |
Art1 |
ADP-ribosyltransferase 1 |
|
increases expression |
EXP |
1 |
159,586,246 |
159,590,797 |
RGD:6480464 |
CTD |
| G |
Art5 |
ADP-ribosyltransferase 5 |
|
increases expression |
EXP |
1 |
159,576,990 |
159,586,949 |
RGD:6480464 |
CTD |
| G |
Art5 |
ADP-ribosyltransferase 5 |
|
multiple interactions |
EXP |
1 |
159,576,990 |
159,586,949 |
RGD:6480464 |
CTD |
| G |
Asah2 |
N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 |
|
decreases expression |
EXP |
1 |
236,000,768 |
236,072,477 |
RGD:6480464 |
CTD |
| G |
Asah2 |
N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 |
|
multiple interactions |
EXP |
1 |
236,000,768 |
236,072,477 |
RGD:6480464 |
CTD |
| G |
Ass1 |
argininosuccinate synthase 1 |
|
increases expression |
EXP |
3 |
10,578,717 |
10,622,332 |
RGD:6480464 |
CTD |
| G |
Ass1 |
argininosuccinate synthase 1 |
|
multiple interactions |
EXP |
3 |
10,578,717 |
10,622,332 |
RGD:6480464 |
CTD |
| G |
Atcay |
ataxia, cerebellar, Cayman type |
|
decreases expression |
EXP |
7 |
9,971,563 |
9,995,528 |
RGD:6480464 |
CTD |
| G |
Atcay |
ataxia, cerebellar, Cayman type |
|
multiple interactions |
EXP |
7 |
9,971,563 |
9,995,528 |
RGD:6480464 |
CTD |
| G |
Atp2a1 |
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
multiple interactions |
EXP |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
multiple interactions |
EXP |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
multiple interactions |
EXP |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
increases activity |
EXP |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
B2m |
beta-2 microglobulin |
|
decreases expression |
ISO |
3 |
108,927,919 |
108,932,718 |
RGD:6480464 |
CTD |
| G |
B4galt6 |
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 |
|
decreases expression |
EXP |
18 |
12,421,062 |
12,478,276 |
RGD:6480464 |
CTD |
| G |
B4galt6 |
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 |
|
multiple interactions |
EXP |
18 |
12,421,062 |
12,478,276 |
RGD:6480464 |
CTD |
| G |
Bad |
BCL2-associated agonist of cell death |
|
decreases phosphorylation |
ISO |
1 |
209,617,373 |
209,626,292 |
RGD:6480464 |
CTD |
| G |
Bad |
BCL2-associated agonist of cell death |
|
increases expression |
ISO |
1 |
209,617,373 |
209,626,292 |
RGD:6480464 |
CTD |
| G |
Bad |
BCL2-associated agonist of cell death |
|
multiple interactions |
ISO |
1 |
209,617,373 |
209,626,292 |
RGD:6480464 |
CTD |
| G |
Bambi |
BMP and activin membrane-bound inhibitor, homolog (Xenopus laevis) |
|
decreases expression |
ISO |
17 |
62,654,385 |
62,658,641 |
RGD:6480464 |
CTD |
| G |
Basp1 |
brain abundant, membrane attached signal protein 1 |
|
decreases expression |
EXP |
2 |
76,877,616 |
76,927,721 |
RGD:6480464 |
CTD |
| G |
Basp1 |
brain abundant, membrane attached signal protein 1 |
|
multiple interactions |
EXP |
2 |
76,877,616 |
76,927,721 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases response to substance |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases response to substance |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
decreases expression |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases stability |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases response to substance |
ISO |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases expression |
ISO |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases phosphorylation |
ISO |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
multiple interactions |
ISO |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
multiple interactions |
ISO |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases expression |
ISO |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases expression |
ISO |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Bcl2l11 |
BCL2-like 11 (apoptosis facilitator) |
|
increases response to substance |
ISO |
3 |
115,692,323 |
115,722,701 |
RGD:6480464 |
CTD |
| G |
Bcl3 |
B-cell CLL/lymphoma 3 |
|
decreases expression |
EXP |
1 |
79,122,801 |
79,137,035 |
RGD:6480464 |
CTD |
| G |
Bcl3 |
B-cell CLL/lymphoma 3 |
|
multiple interactions |
EXP |
1 |
79,122,801 |
79,137,035 |
RGD:6480464 |
CTD |
| G |
Bcr |
breakpoint cluster region |
|
decreases expression |
EXP |
20 |
13,972,773 |
14,097,816 |
RGD:6480464 |
CTD |
| G |
Bcr |
breakpoint cluster region |
|
multiple interactions |
EXP |
20 |
13,972,773 |
14,097,816 |
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Birc2 |
baculoviral IAP repeat-containing 2 |
|
multiple interactions |
ISO |
8 |
4,649,559 |
4,667,733 |
RGD:6480464 |
CTD |
| G |
Birc3 |
baculoviral IAP repeat-containing 3 |
|
multiple interactions |
ISO |
8 |
4,682,202 |
4,696,856 |
RGD:6480464 |
CTD |
| G |
Birc3 |
baculoviral IAP repeat-containing 3 |
|
increases expression |
ISO |
8 |
4,682,202 |
4,696,856 |
RGD:6480464 |
CTD |
| G |
Birc3 |
baculoviral IAP repeat-containing 3 |
|
multiple interactions |
EXP |
8 |
4,682,202 |
4,696,856 |
RGD:6480464 |
CTD |
| G |
Birc3 |
baculoviral IAP repeat-containing 3 |
|
increases expression |
EXP |
8 |
4,682,202 |
4,696,856 |
RGD:6480464 |
CTD |
| G |
Birc3 |
baculoviral IAP repeat-containing 3 |
|
increases expression |
ISO |
8 |
4,682,202 |
4,696,856 |
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bmp2 |
bone morphogenetic protein 2 |
|
multiple interactions |
ISO |
3 |
121,372,692 |
121,381,236 |
RGD:6480464 |
CTD |
| G |
Bmp2 |
bone morphogenetic protein 2 |
|
multiple interactions |
ISO |
3 |
121,372,692 |
121,381,236 |
RGD:6480464 |
CTD |
| G |
Bmp4 |
bone morphogenetic protein 4 |
|
multiple interactions |
ISO |
15 |
22,283,171 |
22,286,757 |
RGD:6480464 |
CTD |
| G |
Bmp4 |
bone morphogenetic protein 4 |
|
affects expression |
ISO |
15 |
22,283,171 |
22,286,757 |
RGD:6480464 |
CTD |
| G |
Bmp4 |
bone morphogenetic protein 4 |
|
multiple interactions |
ISO |
15 |
22,283,171 |
22,286,757 |
RGD:6480464 |
CTD |
| G |
Bmp6 |
bone morphogenetic protein 6 |
|
multiple interactions |
ISO |
17 |
32,380,199 |
32,689,295 |
RGD:6480464 |
CTD |
| G |
Bmp8a |
bone morphogenetic protein 8a |
|
increases expression |
ISO |
5 |
142,627,733 |
142,653,782 |
RGD:6480464 |
CTD |
| G |
Bmp8a |
bone morphogenetic protein 8a |
|
decreases response to substance |
ISO |
5 |
142,627,733 |
142,653,782 |
RGD:6480464 |
CTD |
| G |
Btg1 |
B-cell translocation gene 1, anti-proliferative |
|
increases expression |
ISO |
7 |
34,029,300 |
34,031,557 |
RGD:6480464 |
CTD |
| G |
Btg2 |
BTG family, member 2 |
|
increases expression |
ISO |
13 |
47,026,986 |
47,030,745 |
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
C4a |
complement component 4A (Rodgers blood group) |
|
multiple interactions |
EXP |
20 |
4,106,123 |
4,145,904 |
RGD:6480464 |
CTD |
| G |
C4a |
complement component 4A (Rodgers blood group) |
|
increases expression |
EXP |
20 |
4,106,123 |
4,145,904 |
RGD:6480464 |
CTD |
| G |
Cacna2d1 |
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
|
multiple interactions |
ISO |
4 |
15,139,881 |
15,566,740 |
RGD:6480464 |
CTD |
| G |
Calb1 |
calbindin 1 |
|
decreases expression |
EXP |
5 |
30,455,665 |
30,480,122 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
decreases response to substance |
ISO |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calml4 |
calmodulin-like 4 |
|
multiple interactions |
ISO |
8 |
67,007,122 |
67,018,886 |
RGD:6480464 |
CTD |
| G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
|
decreases expression |
EXP |
18 |
25,404,123 |
25,625,785 |
RGD:6480464 |
CTD |
| G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
|
multiple interactions |
EXP |
18 |
25,404,123 |
25,625,785 |
RGD:6480464 |
CTD |
| G |
Capn2 |
calpain 2, (m/II) large subunit |
|
increases expression |
EXP |
13 |
98,473,367 |
98,524,463 |
RGD:6480464 |
CTD |
| G |
Capn2 |
calpain 2, (m/II) large subunit |
|
multiple interactions |
EXP |
13 |
98,473,367 |
98,524,463 |
RGD:6480464 |
CTD |
| G |
Car4 |
carbonic anhydrase 4 |
|
decreases expression |
EXP |
10 |
73,229,211 |
73,237,707 |
RGD:6480464 |
CTD |
| G |
Car4 |
carbonic anhydrase 4 |
|
multiple interactions |
EXP |
10 |
73,229,211 |
73,237,707 |
RGD:6480464 |
CTD |
| G |
Casp1 |
caspase 1 |
|
multiple interactions |
ISO |
8 |
2,027,976 |
2,036,872 |
RGD:6480464 |
CTD |
| G |
Casp2 |
caspase 2 |
|
decreases expression |
EXP |
4 |
70,029,728 |
70,047,164 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
decreases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
decreases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
multiple interactions |
EXP |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases activity |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases activity |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
EXP |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases cleavage |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
decreases expression |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases expression |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases activity |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases expression |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases expression |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cav1 |
caveolin 1, caveolae protein |
|
multiple interactions |
ISO |
4 |
42,956,102 |
42,989,057 |
RGD:6480464 |
CTD |
| G |
Cav1 |
caveolin 1, caveolae protein |
|
multiple interactions |
ISO |
4 |
42,956,102 |
42,989,057 |
RGD:6480464 |
CTD |
| G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
|
increases expression |
ISO |
20 |
29,997,000 |
30,039,602 |
RGD:6480464 |
CTD |
| G |
Ccdc86 |
coiled-coil domain containing 86 |
|
decreases expression |
ISO |
1 |
213,440,231 |
213,445,812 |
RGD:6480464 |
CTD |
| G |
Cckbr |
cholecystokinin B receptor |
|
decreases expression |
EXP |
1 |
163,156,914 |
163,166,969 |
RGD:6480464 |
CTD |
| G |
Cckbr |
cholecystokinin B receptor |
|
multiple interactions |
EXP |
1 |
163,156,914 |
163,166,969 |
RGD:6480464 |
CTD |
| G |
Ccl17 |
chemokine (C-C motif) ligand 17 |
|
multiple interactions |
ISO |
19 |
10,641,376 |
10,642,827 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl26 |
chemokine (C-C motif) ligand 26 |
|
multiple interactions |
ISO |
12 |
22,265,430 |
22,268,793 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
multiple interactions |
ISO |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
ISO |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
ISO |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
EXP |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Ccl7 |
chemokine (C-C motif) ligand 7 |
|
multiple interactions |
ISO |
10 |
70,267,281 |
70,269,131 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
EXP |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
multiple interactions |
EXP |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases degradation |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases ubiquitination |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd2 |
cyclin D2 |
|
decreases expression |
EXP |
4 |
163,523,817 |
163,546,501 |
RGD:6480464 |
CTD |
| G |
Ccng1 |
cyclin G1 |
|
increases expression |
EXP |
10 |
25,776,380 |
25,782,754 |
RGD:6480464 |
CTD |
| G |
Ccr3 |
chemokine (C-C motif) receptor 3 |
|
decreases expression |
ISO |
8 |
128,759,943 |
128,769,341 |
RGD:6480464 |
CTD |
| G |
Ccr4 |
chemokine (C-C motif) receptor 4 |
|
increases expression |
ISO |
8 |
118,883,148 |
118,884,230 |
RGD:6480464 |
CTD |
| G |
Ccr9 |
chemokine (C-C motif) receptor 9 |
|
increases expression |
ISO |
8 |
128,527,943 |
128,541,982 |
RGD:6480464 |
CTD |
| G |
Cd14 |
CD14 molecule |
|
increases expression |
ISO |
18 |
29,374,593 |
29,376,190 |
RGD:6480464 |
CTD |
| G |
Cd163 |
CD163 molecule |
|
increases expression |
EXP |
4 |
160,394,833 |
160,428,208 |
RGD:6480464 |
CTD |
| G |
Cd24 |
CD24 molecule |
|
increases expression |
EXP |
20 |
47,502,354 |
47,507,663 |
RGD:6480464 |
CTD |
| G |
Cd24 |
CD24 molecule |
|
multiple interactions |
EXP |
20 |
47,502,354 |
47,507,663 |
RGD:6480464 |
CTD |
| G |
Cd28 |
Cd28 molecule |
|
multiple interactions |
ISO |
9 |
59,342,273 |
59,367,743 |
RGD:6480464 |
CTD |
| G |
Cd36 |
CD36 molecule (thrombospondin receptor) |
|
increases expression |
ISO |
4 |
13,471,878 |
13,525,620 |
RGD:6480464 |
CTD |
| G |
Cd36 |
CD36 molecule (thrombospondin receptor) |
|
affects expression |
EXP |
4 |
13,471,878 |
13,525,620 |
RGD:6480464 |
CTD |
| G |
Cd36 |
CD36 molecule (thrombospondin receptor) |
|
multiple interactions |
EXP |
4 |
13,471,878 |
13,525,620 |
RGD:6480464 |
CTD |
| G |
Cd36 |
CD36 molecule (thrombospondin receptor) |
|
increases expression |
EXP |
4 |
13,471,878 |
13,525,620 |
RGD:6480464 |
CTD |
| G |
Cd4 |
Cd4 molecule |
|
multiple interactions |
ISO |
4 |
160,988,512 |
161,014,038 |
RGD:6480464 |
CTD |
| G |
Cd4 |
Cd4 molecule |
|
decreases expression |
ISO |
4 |
160,988,512 |
161,014,038 |
RGD:6480464 |
CTD |
| G |
Cd53 |
Cd53 molecule |
|
increases expression |
ISO |
2 |
202,186,125 |
202,234,570 |
RGD:6480464 |
CTD |
| G |
Cd68 |
Cd68 molecule |
|
increases expression |
ISO |
10 |
56,481,701 |
56,483,580 |
RGD:6480464 |
CTD |
| G |
Cd69 |
Cd69 molecule |
|
increases expression |
ISO |
4 |
166,527,683 |
166,535,601 |
RGD:6480464 |
CTD |
| G |
Cda |
cytidine deaminase |
|
increases activity |
ISO |
5 |
157,117,303 |
157,143,989 |
RGD:6480464 |
CTD |
| G |
Cdc42 |
cell division cycle 42 (GTP binding protein) |
|
multiple interactions |
ISO |
5 |
156,106,123 |
156,143,040 |
RGD:6480464 |
CTD |
| G |
Cdca7 |
cell division cycle associated 7 |
|
decreases expression |
EXP |
3 |
54,948,493 |
54,959,128 |
RGD:6480464 |
CTD |
| G |
Cdca7 |
cell division cycle associated 7 |
|
multiple interactions |
EXP |
3 |
54,948,493 |
54,959,128 |
RGD:6480464 |
CTD |
| G |
Cdh13 |
cadherin 13 |
|
multiple interactions |
ISO |
19 |
48,507,173 |
49,575,123 |
RGD:6480464 |
CTD |
| G |
Cdh13 |
cadherin 13 |
|
decreases expression |
EXP |
19 |
48,507,173 |
49,575,123 |
RGD:6480464 |
CTD |
| G |
Cdh13 |
cadherin 13 |
|
multiple interactions |
EXP |
19 |
48,507,173 |
49,575,123 |
RGD:6480464 |
CTD |
| G |
Cdk1 |
cyclin-dependent kinase 1 |
|
decreases expression |
EXP |
20 |
20,018,044 |
20,044,030 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
multiple interactions |
ISO |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
decreases activity |
ISO |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
decreases expression |
ISO |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
multiple interactions |
EXP |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
multiple interactions |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
multiple interactions |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
|
multiple interactions |
EXP |
15 |
22,617,409 |
22,624,922 |
RGD:6480464 |
CTD |
| G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
|
decreases expression |
EXP |
15 |
22,617,409 |
22,624,922 |
RGD:6480464 |
CTD |
| G |
Cdo1 |
cysteine dioxygenase, type I |
|
multiple interactions |
ISO |
18 |
40,914,028 |
40,928,671 |
RGD:6480464 |
CTD |
| G |
Ceacam1 |
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
|
increases expression |
EXP |
1 |
80,742,540 |
80,758,943 |
RGD:6480464 |
CTD |
| G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
1 |
87,626,111 |
87,627,499 |
RGD:6480464 |
CTD |
| G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
1 |
87,626,111 |
87,627,499 |
RGD:6480464 |
CTD |
| G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
1 |
87,626,111 |
87,627,499 |
RGD:6480464 |
CTD |
| G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
multiple interactions |
ISO |
1 |
87,626,111 |
87,627,499 |
RGD:6480464 |
CTD |
| G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
increases expression |
EXP |
1 |
87,626,111 |
87,627,499 |
RGD:6480464 |
CTD |
| G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
|
increases expression |
EXP |
1 |
87,626,111 |
87,627,499 |
RGD:6480464 |
CTD |
| G |
Cebpb |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
ISO |
3 |
158,826,021 |
158,827,848 |
RGD:6480464 |
CTD |
| G |
Cebpb |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
EXP |
3 |
158,826,021 |
158,827,848 |
RGD:6480464 |
CTD |
| G |
Cebpb |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
ISO |
3 |
158,826,021 |
158,827,848 |
RGD:6480464 |
CTD |
| G |
Cebpb |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
EXP |
3 |
158,826,021 |
158,827,848 |
RGD:6480464 |
CTD |
| G |
Cebpb |
CCAAT/enhancer binding protein (C/EBP), beta |
|
increases expression |
EXP |
3 |
158,826,021 |
158,827,848 |
RGD:6480464 |
CTD |
| G |
Cebpb |
CCAAT/enhancer binding protein (C/EBP), beta |
|
multiple interactions |
EXP |
3 |
158,826,021 |
158,827,848 |
RGD:6480464 |
CTD |
| G |
Cebpb |
CCAAT/enhancer binding protein (C/EBP), beta |
|
increases expression |
EXP |
3 |
158,826,021 |
158,827,848 |
RGD:6480464 |
CTD |
| G |
Cebpd |
CCAAT/enhancer binding protein (C/EBP), delta |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cebpd |
CCAAT/enhancer binding protein (C/EBP), delta |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cebpd |
CCAAT/enhancer binding protein (C/EBP), delta |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Celf2 |
CUGBP, Elav-like family member 2 |
|
multiple interactions |
ISO |
17 |
82,708,354 |
83,025,139 |
RGD:6480464 |
CTD |
| G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
|
decreases expression |
ISO |
8 |
113,882,883 |
113,923,950 |
RGD:6480464 |
CTD |
| G |
Ces1d |
carboxylesterase 1D |
|
decreases expression |
EXP |
19 |
14,928,539 |
14,967,082 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
affects expression |
EXP |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
increases expression |
ISO |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
multiple interactions |
EXP |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
decreases expression |
EXP |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
increases expression |
EXP |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Cfd |
complement factor D (adipsin) |
|
decreases expression |
ISO |
7 |
11,325,538 |
11,327,261 |
RGD:6480464 |
CTD |
| G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
|
increases expression |
ISO |
9 |
57,309,836 |
57,356,635 |
RGD:6480464 |
CTD |
| G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
|
multiple interactions |
ISO |
9 |
57,309,836 |
57,356,635 |
RGD:6480464 |
CTD |
| G |
Chi3l1 |
chitinase 3-like 1 (cartilage glycoprotein-39) |
|
decreases expression |
ISO |
13 |
47,139,658 |
47,147,591 |
RGD:6480464 |
CTD |
| G |
Chid1 |
chitinase domain containing 1 |
|
multiple interactions |
ISO |
1 |
201,683,719 |
201,718,785 |
RGD:6480464 |
CTD |
| G |
Chid1 |
chitinase domain containing 1 |
|
increases expression |
ISO |
1 |
201,683,719 |
201,718,785 |
RGD:6480464 |
CTD |
| G |
Chrnd |
cholinergic receptor, nicotinic, delta (muscle) |
|
increases expression |
EXP |
9 |
85,996,421 |
86,004,839 |
RGD:6480464 |
CTD |
| G |
Chrnd |
cholinergic receptor, nicotinic, delta (muscle) |
|
multiple interactions |
EXP |
9 |
85,996,421 |
86,004,839 |
RGD:6480464 |
CTD |
| G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
|
multiple interactions |
ISO |
1 |
249,122,845 |
249,158,369 |
RGD:6480464 |
CTD |
| G |
Cib2 |
calcium and integrin binding family member 2 |
|
multiple interactions |
EXP |
8 |
58,093,941 |
58,110,808 |
RGD:6480464 |
CTD |
| G |
Cib2 |
calcium and integrin binding family member 2 |
|
decreases expression |
EXP |
8 |
58,093,941 |
58,110,808 |
RGD:6480464 |
CTD |
| G |
Cidea |
cell death-inducing DFFA-like effector a |
|
increases expression |
EXP |
18 |
63,871,538 |
63,896,975 |
RGD:6480464 |
CTD |
| G |
Cidea |
cell death-inducing DFFA-like effector a |
|
multiple interactions |
EXP |
18 |
63,871,538 |
63,896,975 |
RGD:6480464 |
CTD |
| G |
Cirbp |
cold inducible RNA binding protein |
|
decreases expression |
ISO |
7 |
11,047,003 |
11,050,820 |
RGD:6480464 |
CTD |
| G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
|
multiple interactions |
ISO |
1 |
12,721,500 |
12,723,943 |
RGD:6480464 |
CTD |
| G |
Ckb |
creatine kinase, brain |
|
increases expression |
EXP |
6 |
136,452,215 |
136,455,122 |
RGD:6480464 |
CTD |
| G |
Clcn4 |
chloride channel, voltage-sensitive 4 |
|
decreases expression |
EXP |
X |
44,355,648 |
44,419,524 |
RGD:6480464 |
CTD |
| G |
Cln6 |
ceroid-lipofuscinosis, neuronal 6, late infantile, variant |
|
decreases expression |
EXP |
8 |
66,987,057 |
67,002,013 |
RGD:6480464 |
CTD |
| G |
Cln6 |
ceroid-lipofuscinosis, neuronal 6, late infantile, variant |
|
multiple interactions |
EXP |
8 |
66,987,057 |
67,002,013 |
RGD:6480464 |
CTD |
| G |
Clu |
clusterin |
|
decreases expression |
EXP |
15 |
45,365,779 |
45,405,314 |
RGD:6480464 |
CTD |
| G |
Clu |
clusterin |
|
multiple interactions |
EXP |
15 |
45,365,779 |
45,405,314 |
RGD:6480464 |
CTD |
| G |
Cnksr1 |
connector enhancer of kinase suppressor of Ras 1 |
|
increases expression |
EXP |
5 |
152,972,551 |
152,983,208 |
RGD:6480464 |
CTD |
| G |
Cnksr1 |
connector enhancer of kinase suppressor of Ras 1 |
|
multiple interactions |
EXP |
5 |
152,972,551 |
152,983,208 |
RGD:6480464 |
CTD |
| G |
Cntn1 |
contactin 1 |
|
decreases expression |
EXP |
7 |
130,658,836 |
130,845,071 |
RGD:6480464 |
CTD |
| G |
Cntn1 |
contactin 1 |
|
multiple interactions |
EXP |
7 |
130,658,836 |
130,845,071 |
RGD:6480464 |
CTD |
| G |
Col11a1 |
collagen, type XI, alpha 1 |
|
multiple interactions |
ISO |
2 |
209,996,467 |
210,193,379 |
RGD:6480464 |
CTD |
| G |
Col15a1 |
collagen, type XV, alpha 1 |
|
multiple interactions |
ISO |
5 |
63,825,907 |
63,930,633 |
RGD:6480464 |
CTD |
| G |
Col15a1 |
collagen, type XV, alpha 1 |
|
multiple interactions |
EXP |
5 |
63,825,907 |
63,930,633 |
RGD:6480464 |
CTD |
| G |
Col15a1 |
collagen, type XV, alpha 1 |
|
decreases expression |
EXP |
5 |
63,825,907 |
63,930,633 |
RGD:6480464 |
CTD |
| G |
Col1a1 |
collagen, type I, alpha 1 |
|
decreases expression |
EXP |
10 |
83,622,438 |
83,639,368 |
RGD:6480464 |
CTD |
| G |
Col2a1 |
collagen, type II, alpha 1 |
|
multiple interactions |
ISO |
7 |
136,679,219 |
136,707,976 |
RGD:6480464 |
CTD |
| G |
Col2a1 |
collagen, type II, alpha 1 |
|
affects expression |
ISO |
7 |
136,679,219 |
136,707,976 |
RGD:6480464 |
CTD |
| G |
Col4a1 |
collagen, type IV, alpha 1 |
|
multiple interactions |
ISO |
16 |
83,045,183 |
83,157,835 |
RGD:6480464 |
CTD |
| G |
Col5a1 |
collagen, type V, alpha 1 |
|
decreases expression |
EXP |
3 |
6,826,169 |
6,971,054 |
RGD:6480464 |
CTD |
| G |
Col5a1 |
collagen, type V, alpha 1 |
|
multiple interactions |
EXP |
3 |
6,826,169 |
6,971,054 |
RGD:6480464 |
CTD |
| G |
Col5a2 |
collagen, type V, alpha 2 |
|
decreases expression |
EXP |
9 |
44,374,113 |
44,525,086 |
RGD:6480464 |
CTD |
| G |
Col5a2 |
collagen, type V, alpha 2 |
|
multiple interactions |
EXP |
9 |
44,374,113 |
44,525,086 |
RGD:6480464 |
CTD |
| G |
Col5a3 |
collagen, type V, alpha 3 |
|
multiple interactions |
EXP |
8 |
19,789,061 |
19,834,241 |
RGD:6480464 |
CTD |
| G |
Col5a3 |
collagen, type V, alpha 3 |
|
decreases expression |
EXP |
8 |
19,789,061 |
19,834,241 |
RGD:6480464 |
CTD |
| G |
Col9a1 |
collagen, type IX, alpha 1 |
|
affects expression |
ISO |
9 |
22,907,157 |
22,990,836 |
RGD:6480464 |
CTD |
| G |
Comt |
catechol-O-methyltransferase |
|
increases expression |
EXP |
11 |
84,561,591 |
84,581,713 |
RGD:6480464 |
CTD |
| G |
Comt |
catechol-O-methyltransferase |
|
multiple interactions |
EXP |
11 |
84,561,591 |
84,581,713 |
RGD:6480464 |
CTD |
| G |
Copb2 |
coatomer protein complex, subunit beta 2 (beta prime) |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Copb2 |
coatomer protein complex, subunit beta 2 (beta prime) |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cp |
ceruloplasmin (ferroxidase) |
|
multiple interactions |
ISO |
2 |
105,086,278 |
105,135,367 |
RGD:6480464 |
CTD |
| G |
Cp |
ceruloplasmin (ferroxidase) |
|
increases expression |
EXP |
2 |
105,086,278 |
105,135,367 |
RGD:6480464 |
CTD |
| G |
Cp |
ceruloplasmin (ferroxidase) |
|
multiple interactions |
EXP |
2 |
105,086,278 |
105,135,367 |
RGD:6480464 |
CTD |
| G |
Cpa1 |
carboxypeptidase A1 (pancreatic) |
|
decreases expression |
EXP |
4 |
57,549,260 |
57,555,361 |
RGD:6480464 |
CTD |
| G |
Cpa1 |
carboxypeptidase A1 (pancreatic) |
|
multiple interactions |
EXP |
4 |
57,549,260 |
57,555,361 |
RGD:6480464 |
CTD |
| G |
Cpe |
carboxypeptidase E |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cpe |
carboxypeptidase E |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cpn1 |
carboxypeptidase N, polypeptide 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cps1 |
carbamoyl-phosphate synthetase 1 |
|
increases expression |
ISO |
9 |
65,907,211 |
66,017,942 |
RGD:6480464 |
CTD |
| G |
Cps1 |
carbamoyl-phosphate synthetase 1 |
|
increases expression |
EXP |
9 |
65,907,211 |
66,017,942 |
RGD:6480464 |
CTD |
| G |
Crabp2 |
cellular retinoic acid binding protein 2 |
|
decreases expression |
ISO |
2 |
180,029,801 |
180,034,147 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
increases phosphorylation |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
increases expression |
EXP |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Crisp1 |
cysteine-rich secretory protein 1 |
|
decreases expression |
EXP |
9 |
16,975,151 |
17,002,149 |
RGD:6480464 |
CTD |
| G |
Crisp1 |
cysteine-rich secretory protein 1 |
|
multiple interactions |
EXP |
9 |
16,975,151 |
17,002,149 |
RGD:6480464 |
CTD |
| G |
Crkl |
v-crk sarcoma virus CT10 oncogene homolog (avian)-like |
|
multiple interactions |
ISO |
11 |
85,520,244 |
85,554,667 |
RGD:6480464 |
CTD |
| G |
Cryab |
crystallin, alpha B |
|
increases expression |
ISO |
8 |
54,107,824 |
54,111,502 |
RGD:6480464 |
CTD |
| G |
Cryab |
crystallin, alpha B |
|
multiple interactions |
ISO |
8 |
54,107,824 |
54,111,502 |
RGD:6480464 |
CTD |
| G |
Csf1 |
colony stimulating factor 1 (macrophage) |
|
multiple interactions |
ISO |
2 |
203,292,765 |
203,307,968 |
RGD:6480464 |
CTD |
| G |
Csf1r |
colony stimulating factor 1 receptor |
|
increases expression |
ISO |
18 |
57,080,324 |
57,107,295 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
|
increases expression |
ISO |
10 |
87,473,990 |
87,476,365 |
RGD:6480464 |
CTD |
| G |
Csrp3 |
cysteine and glycine-rich protein 3 (cardiac LIM protein) |
|
increases expression |
EXP |
1 |
98,601,681 |
98,611,747 |
RGD:6480464 |
CTD |
| G |
Csrp3 |
cysteine and glycine-rich protein 3 (cardiac LIM protein) |
|
multiple interactions |
EXP |
1 |
98,601,681 |
98,611,747 |
RGD:6480464 |
CTD |
| G |
Cst6 |
cystatin E/M |
|
multiple interactions |
ISO |
1 |
207,991,313 |
207,993,021 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
decreases expression |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
decreases expression |
EXP |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Ctsl1 |
cathepsin L1 |
|
increases expression |
EXP |
17 |
6,288,013 |
6,294,174 |
RGD:6480464 |
CTD |
| G |
Ctsl1 |
cathepsin L1 |
|
increases expression |
EXP |
17 |
6,288,013 |
6,294,174 |
RGD:6480464 |
CTD |
| G |
Ctsl1 |
cathepsin L1 |
|
multiple interactions |
EXP |
17 |
6,288,013 |
6,294,174 |
RGD:6480464 |
CTD |
| G |
Cx3cl1 |
chemokine (C-X3-C motif) ligand 1 |
|
multiple interactions |
ISO |
19 |
10,666,940 |
10,676,424 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
EXP |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
EXP |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
multiple interactions |
ISO |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cxcl12 |
chemokine (C-X-C motif) ligand 12 |
|
multiple interactions |
ISO |
4 |
153,503,576 |
153,516,423 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
EXP |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
EXP |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cxcl5 |
chemokine (C-X-C motif) ligand 5 |
|
multiple interactions |
ISO |
14 |
18,825,357 |
18,826,269 |
RGD:6480464 |
CTD |
| G |
Cxcr4 |
chemokine (C-X-C motif) receptor 4 |
|
increases expression |
ISO |
13 |
41,308,286 |
41,312,190 |
RGD:6480464 |
CTD |
| G |
Cxcr4 |
chemokine (C-X-C motif) receptor 4 |
|
multiple interactions |
ISO |
13 |
41,308,286 |
41,312,190 |
RGD:6480464 |
CTD |
| G |
Cxcr4 |
chemokine (C-X-C motif) receptor 4 |
|
increases expression |
ISO |
13 |
41,308,286 |
41,312,190 |
RGD:6480464 |
CTD |
| G |
Cxcr7 |
chemokine (C-X-C motif) receptor 7 |
|
decreases expression |
ISO |
9 |
89,343,528 |
89,355,053 |
RGD:6480464 |
CTD |
| G |
Cyb5r3 |
cytochrome b5 reductase 3 |
|
decreases expression |
EXP |
7 |
121,187,821 |
121,205,382 |
RGD:6480464 |
CTD |
| G |
Cybb |
cytochrome b-245, beta polypeptide |
|
multiple interactions |
ISO |
X |
25,514,572 |
25,547,181 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
multiple interactions |
ISO |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
increases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases activity |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
decreases expression |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
affects expression |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
multiple interactions |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
increases expression |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
multiple interactions |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
multiple interactions |
EXP |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
|
affects activity |
ISO |
3 |
161,542,131 |
161,553,801 |
RGD:6480464 |
CTD |
| G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
|
affects expression |
ISO |
3 |
161,542,131 |
161,553,801 |
RGD:6480464 |
CTD |
| G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
3 |
161,542,131 |
161,553,801 |
RGD:6480464 |
CTD |
| G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
9 |
74,039,204 |
74,068,648 |
RGD:6480464 |
CTD |
| G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
9 |
74,039,204 |
74,068,648 |
RGD:6480464 |
CTD |
| G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
|
affects activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
|
affects expression |
EXP |
1 |
82,006,828 |
82,020,282 |
RGD:6480464 |
CTD |
| G |
Cyp2a2 |
cytochrome P450, family 2, subfamily a, polypeptide 2 |
|
affects expression |
EXP |
1 |
82,039,229 |
82,064,293 |
RGD:6480464 |
CTD |
| G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
|
multiple interactions |
ISO |
1 |
81,944,896 |
81,953,007 |
RGD:6480464 |
CTD |
| G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
|
increases activity |
ISO |
1 |
81,944,896 |
81,953,007 |
RGD:6480464 |
CTD |
| G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
|
increases expression |
ISO |
1 |
81,944,896 |
81,953,007 |
RGD:6480464 |
CTD |
| G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
|
multiple interactions |
EXP |
1 |
81,266,828 |
81,290,471 |
RGD:6480464 |
CTD |
| G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
|
increases expression |
EXP |
1 |
81,266,828 |
81,290,471 |
RGD:6480464 |
CTD |
| G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
|
increases expression |
ISO |
1 |
81,266,828 |
81,290,471 |
RGD:6480464 |
CTD |
| G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
|
affects expression |
EXP |
1 |
81,839,930 |
81,852,366 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
affects expression |
EXP |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases expression |
EXP |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
multiple interactions |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
multiple interactions |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases expression |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases expression |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases expression |
EXP |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases expression |
EXP |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
affects binding |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
increases expression |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases expression |
EXP |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
decreases expression |
EXP |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases expression |
EXP |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
|
affects expression |
EXP |
12 |
9,086,752 |
9,136,606 |
RGD:6480464 |
CTD |
| G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
|
increases expression |
EXP |
12 |
9,086,752 |
9,136,606 |
RGD:6480464 |
CTD |
| G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
|
increases expression |
ISO |
12 |
9,086,752 |
9,136,606 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
EXP |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects expression |
EXP |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
EXP |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a23/3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1 |
|
multiple interactions |
EXP |
12 |
9,567,120 |
9,595,974 |
RGD:6480464 |
CTD |
| G |
Cyp3a23/3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1 |
|
increases expression |
EXP |
12 |
9,567,120 |
9,595,974 |
RGD:6480464 |
CTD |
| G |
Cyp3a23/3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1 |
|
increases expression |
EXP |
12 |
9,567,120 |
9,595,974 |
RGD:6480464 |
CTD |
| G |
Cyp3a23/3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1 |
|
multiple interactions |
EXP |
12 |
9,567,120 |
9,595,974 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
increases expression |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
increases expression |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
decreases expression |
EXP |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
|
increases expression |
ISO |
5 |
135,876,140 |
135,893,753 |
RGD:6480464 |
CTD |
| G |
Cyp51 |
cytochrome P450, family 51 |
|
decreases expression |
ISO |
4 |
26,752,677 |
26,771,131 |
RGD:6480464 |
CTD |
| G |
Cyp51 |
cytochrome P450, family 51 |
|
affects expression |
EXP |
4 |
26,752,677 |
26,771,131 |
RGD:6480464 |
CTD |
| G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
5 |
19,707,159 |
19,716,856 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
multiple interactions |
EXP |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
increases expression |
EXP |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
multiple interactions |
EXP |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
decreases expression |
EXP |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Dbp |
D site of albumin promoter (albumin D-box) binding protein |
|
decreases expression |
EXP |
1 |
96,173,573 |
96,178,485 |
RGD:6480464 |
CTD |
| G |
Dbp |
D site of albumin promoter (albumin D-box) binding protein |
|
increases expression |
EXP |
1 |
96,173,573 |
96,178,485 |
RGD:6480464 |
CTD |
| G |
Dcn |
decorin |
|
multiple interactions |
ISO |
7 |
35,004,234 |
35,045,191 |
RGD:6480464 |
CTD |
| G |
Ddit4 |
DNA-damage-inducible transcript 4 |
|
increases expression |
ISO |
20 |
27,252,273 |
27,254,371 |
RGD:6480464 |
CTD |
| G |
Ddit4 |
DNA-damage-inducible transcript 4 |
|
multiple interactions |
EXP |
20 |
27,252,273 |
27,254,371 |
RGD:6480464 |
CTD |
| G |
Ddit4 |
DNA-damage-inducible transcript 4 |
|
increases expression |
EXP |
20 |
27,252,273 |
27,254,371 |
RGD:6480464 |
CTD |
| G |
Decr1 |
2,4-dienoyl CoA reductase 1, mitochondrial |
|
increases expression |
EXP |
5 |
30,492,196 |
30,520,172 |
RGD:6480464 |
CTD |
| G |
Degs1 |
delta(4)-desaturase, sphingolipid 1 |
|
decreases expression |
EXP |
13 |
98,242,981 |
98,249,638 |
RGD:6480464 |
CTD |
| G |
Degs1 |
delta(4)-desaturase, sphingolipid 1 |
|
multiple interactions |
EXP |
13 |
98,242,981 |
98,249,638 |
RGD:6480464 |
CTD |
| G |
Dfna5 |
deafness, autosomal dominant 5 (human) |
|
increases expression |
ISO |
4 |
78,431,841 |
78,492,217 |
RGD:6480464 |
CTD |
| G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
|
multiple interactions |
ISO |
7 |
114,552,051 |
114,562,423 |
RGD:6480464 |
CTD |
| G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
|
increases expression |
EXP |
1 |
156,447,588 |
156,478,740 |
RGD:6480464 |
CTD |
| G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
|
multiple interactions |
EXP |
1 |
156,447,588 |
156,478,740 |
RGD:6480464 |
CTD |
| G |
Diablo |
diablo, IAP-binding mitochondrial protein |
|
affects localization |
ISO |
12 |
34,196,347 |
34,209,633 |
RGD:6480464 |
CTD |
| G |
Diablo |
diablo, IAP-binding mitochondrial protein |
|
multiple interactions |
ISO |
12 |
34,196,347 |
34,209,633 |
RGD:6480464 |
CTD |
| G |
Dio3 |
deiodinase, iodothyronine, type III |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Dnaja1 |
DnaJ (Hsp40) homolog, subfamily A, member 1 |
|
increases expression |
ISO |
5 |
58,100,794 |
58,111,705 |
RGD:6480464 |
CTD |
| G |
Dnajb9 |
DnaJ (Hsp40) homolog, subfamily B, member 9 |
|
multiple interactions |
ISO |
6 |
63,583,033 |
63,587,247 |
RGD:6480464 |
CTD |
| G |
Dnajb9 |
DnaJ (Hsp40) homolog, subfamily B, member 9 |
|
increases expression |
ISO |
6 |
63,583,033 |
63,587,247 |
RGD:6480464 |
CTD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
increases expression |
ISO |
10 |
16,942,913 |
16,945,696 |
RGD:6480464 |
CTD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
multiple interactions |
ISO |
10 |
16,942,913 |
16,945,696 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases expression |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Ednrb |
endothelin receptor type B |
|
multiple interactions |
EXP |
15 |
87,893,141 |
87,898,700 |
RGD:6480464 |
CTD |
| G |
Eef1a2 |
eukaryotic translation elongation factor 1 alpha 2 |
|
increases expression |
ISO |
3 |
170,295,327 |
170,304,505 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
EXP |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
EXP |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
EXP |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
multiple interactions |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
increases expression |
EXP |
16 |
69,110,522 |
69,123,895 |
RGD:6480464 |
CTD |
| G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
multiple interactions |
EXP |
16 |
69,110,522 |
69,123,895 |
RGD:6480464 |
CTD |
| G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
|
increases expression |
EXP |
5 |
156,809,618 |
156,979,249 |
RGD:6480464 |
CTD |
| G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
|
multiple interactions |
EXP |
5 |
156,809,618 |
156,979,249 |
RGD:6480464 |
CTD |
| G |
Elovl3 |
ELOVL fatty acid elongase 3 |
|
multiple interactions |
ISO |
1 |
251,351,908 |
251,355,736 |
RGD:6480464 |
CTD |
| G |
Elovl6 |
ELOVL fatty acid elongase 6 |
|
multiple interactions |
ISO |
2 |
226,946,573 |
227,054,321 |
RGD:6480464 |
CTD |
| G |
Emb |
embigin |
|
multiple interactions |
ISO |
2 |
49,098,743 |
49,155,221 |
RGD:6480464 |
CTD |
| G |
Emp1 |
epithelial membrane protein 1 |
|
multiple interactions |
ISO |
4 |
172,315,122 |
172,335,536 |
RGD:6480464 |
CTD |
| G |
Emp2 |
epithelial membrane protein 2 |
|
multiple interactions |
ISO |
10 |
5,311,157 |
5,348,038 |
RGD:6480464 |
CTD |
| G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
|
multiple interactions |
ISO |
7 |
91,295,824 |
91,377,850 |
RGD:6480464 |
CTD |
| G |
Ep300 |
E1A binding protein p300 |
|
multiple interactions |
EXP |
7 |
119,938,507 |
120,008,886 |
RGD:6480464 |
CTD |
| G |
Epha7 |
Eph receptor A7 |
|
multiple interactions |
EXP |
5 |
44,728,037 |
44,878,332 |
RGD:6480464 |
CTD |
| G |
Epha7 |
Eph receptor A7 |
|
decreases expression |
EXP |
5 |
44,728,037 |
44,878,332 |
RGD:6480464 |
CTD |
| G |
Ephx2 |
epoxide hydrolase 2, cytoplasmic |
|
multiple interactions |
ISO |
15 |
45,497,660 |
45,556,101 |
RGD:6480464 |
CTD |
| G |
Ephx2 |
epoxide hydrolase 2, cytoplasmic |
|
increases expression |
EXP |
15 |
45,497,660 |
45,556,101 |
RGD:6480464 |
CTD |
| G |
Erbb4 |
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) |
|
increases expression |
ISO |
9 |
66,843,898 |
67,967,970 |
RGD:6480464 |
CTD |
| G |
Ereg |
epiregulin |
|
increases expression |
ISO |
14 |
18,521,069 |
18,534,844 |
RGD:6480464 |
CTD |
| G |
Erp29 |
endoplasmic reticulum protein 29 |
|
decreases expression |
EXP |
12 |
36,225,110 |
36,231,363 |
RGD:6480464 |
CTD |
| G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
|
increases expression |
EXP |
5 |
168,012,683 |
168,025,963 |
RGD:6480464 |
CTD |
| G |
Espl1 |
extra spindle pole bodies homolog 1 (S. cerevisiae) |
|
multiple interactions |
EXP |
7 |
141,048,197 |
141,074,383 |
RGD:6480464 |
CTD |
| G |
Espl1 |
extra spindle pole bodies homolog 1 (S. cerevisiae) |
|
decreases expression |
EXP |
7 |
141,048,197 |
141,074,383 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
decreases expression |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Ets1 |
v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) |
|
decreases expression |
EXP |
8 |
32,481,694 |
32,545,237 |
RGD:6480464 |
CTD |
| G |
Ets2 |
v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) |
|
increases expression |
ISO |
11 |
36,014,047 |
36,030,833 |
RGD:6480464 |
CTD |
| G |
Evl |
Enah/Vasp-like |
|
multiple interactions |
EXP |
6 |
132,952,804 |
133,019,870 |
RGD:6480464 |
CTD |
| G |
Evl |
Enah/Vasp-like |
|
decreases expression |
EXP |
6 |
132,952,804 |
133,019,870 |
RGD:6480464 |
CTD |
| G |
Exoc2 |
exocyst complex component 2 |
|
decreases expression |
EXP |
17 |
39,951,129 |
40,125,385 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
EXP |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
affects expression |
EXP |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2r |
coagulation factor II (thrombin) receptor |
|
increases expression |
ISO |
2 |
25,985,800 |
25,989,072 |
RGD:6480464 |
CTD |
| G |
F2r |
coagulation factor II (thrombin) receptor |
|
affects expression |
EXP |
2 |
25,985,800 |
25,989,072 |
RGD:6480464 |
CTD |
| G |
F2r |
coagulation factor II (thrombin) receptor |
|
increases expression |
EXP |
2 |
25,985,800 |
25,989,072 |
RGD:6480464 |
CTD |
| G |
F2r |
coagulation factor II (thrombin) receptor |
|
multiple interactions |
EXP |
2 |
25,985,800 |
25,989,072 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
multiple interactions |
ISO |
2 |
218,371,050 |
218,382,645 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
multiple interactions |
ISO |
2 |
218,371,050 |
218,382,645 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
multiple interactions |
EXP |
2 |
218,371,050 |
218,382,645 |
RGD:6480464 |
CTD |
| G |
Fabp1 |
fatty acid binding protein 1, liver |
|
decreases expression |
EXP |
4 |
104,412,200 |
104,415,981 |
RGD:6480464 |
CTD |
| G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
ISO |
2 |
93,536,133 |
93,540,734 |
RGD:6480464 |
CTD |
| G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
ISO |
2 |
93,536,133 |
93,540,734 |
RGD:6480464 |
CTD |
| G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
ISO |
2 |
93,536,133 |
93,540,734 |
RGD:6480464 |
CTD |
| G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
EXP |
2 |
93,536,133 |
93,540,734 |
RGD:6480464 |
CTD |
| G |
Fads1 |
fatty acid desaturase 1 |
|
decreases expression |
EXP |
1 |
212,670,792 |
212,685,718 |
RGD:6480464 |
CTD |
| G |
Fah |
fumarylacetoacetate hydrolase |
|
increases expression |
EXP |
1 |
140,851,975 |
140,876,187 |
RGD:6480464 |
CTD |
| G |
Fah |
fumarylacetoacetate hydrolase |
|
multiple interactions |
EXP |
1 |
140,851,975 |
140,876,187 |
RGD:6480464 |
CTD |
| G |
Fam216a |
family with sequence similarity 216, member A |
|
decreases expression |
ISO |
12 |
35,392,970 |
35,402,113 |
RGD:6480464 |
CTD |
| G |
Fam65b |
family with sequence similarity 65, member B |
|
increases expression |
ISO |
17 |
47,394,370 |
47,492,203 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
multiple interactions |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
multiple interactions |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
decreases expression |
EXP |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
decreases expression |
ISO |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
decreases secretion |
ISO |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
decreases expression |
EXP |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Fasn |
fatty acid synthase |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Fbp2 |
fructose-1,6-bisphosphatase 2 |
|
decreases expression |
EXP |
17 |
7,824,298 |
7,841,661 |
RGD:6480464 |
CTD |
| G |
Fbp2 |
fructose-1,6-bisphosphatase 2 |
|
multiple interactions |
EXP |
17 |
7,824,298 |
7,841,661 |
RGD:6480464 |
CTD |
| G |
Fbxo32 |
F-box protein 32 |
|
multiple interactions |
ISO |
7 |
94,909,568 |
94,942,444 |
RGD:6480464 |
CTD |
| G |
Fbxo32 |
F-box protein 32 |
|
increases expression |
ISO |
7 |
94,909,568 |
94,942,444 |
RGD:6480464 |
CTD |
| G |
Fbxo32 |
F-box protein 32 |
|
increases expression |
EXP |
7 |
94,909,568 |
94,942,444 |
RGD:6480464 |
CTD |
| G |
Fbxo32 |
F-box protein 32 |
|
multiple interactions |
EXP |
7 |
94,909,568 |
94,942,444 |
RGD:6480464 |
CTD |
| G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
|
increases expression |
EXP |
15 |
42,425,336 |
42,453,390 |
RGD:6480464 |
CTD |
| G |
Fdps |
farnesyl diphosphate synthase |
|
multiple interactions |
ISO |
2 |
181,138,474 |
181,177,903 |
RGD:6480464 |
CTD |
| G |
Fdx1 |
ferredoxin 1 |
|
multiple interactions |
ISO |
8 |
55,291,396 |
55,310,507 |
RGD:6480464 |
CTD |
| G |
Fdx1 |
ferredoxin 1 |
|
decreases expression |
EXP |
8 |
55,291,396 |
55,310,507 |
RGD:6480464 |
CTD |
| G |
Fdx1 |
ferredoxin 1 |
|
multiple interactions |
EXP |
8 |
55,291,396 |
55,310,507 |
RGD:6480464 |
CTD |
| G |
Fgb |
fibrinogen beta chain |
|
decreases expression |
EXP |
2 |
174,768,193 |
174,775,102 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf7 |
fibroblast growth factor 7 |
|
multiple interactions |
ISO |
3 |
113,468,427 |
113,517,538 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
multiple interactions |
ISO |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
decreases expression |
EXP |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
multiple interactions |
EXP |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
decreases response to substance |
ISO |
14 |
82,683,191 |
82,697,229 |
RGD:6480464 |
CTD |
| G |
Fhl1 |
four and a half LIM domains 1 |
|
increases expression |
ISO |
X |
141,315,765 |
141,329,278 |
RGD:6480464 |
CTD |
| G |
Figf |
c-fos induced growth factor |
|
multiple interactions |
ISO |
X |
50,830,612 |
50,864,445 |
RGD:6480464 |
CTD |
| G |
Fkbp4 |
FK506 binding protein 4 |
|
increases expression |
ISO |
4 |
165,448,027 |
165,456,481 |
RGD:6480464 |
CTD |
| G |
Fkbp4 |
FK506 binding protein 4 |
|
multiple interactions |
ISO |
4 |
165,448,027 |
165,456,481 |
RGD:6480464 |
CTD |
| G |
Fkbp5 |
FK506 binding protein 5 |
|
increases expression |
ISO |
20 |
6,637,478 |
6,686,768 |
RGD:6480464 |
CTD |
| G |
Fkbp5 |
FK506 binding protein 5 |
|
increases expression |
ISO |
20 |
6,637,478 |
6,686,768 |
RGD:6480464 |
CTD |
| G |
Fkbp5 |
FK506 binding protein 5 |
|
multiple interactions |
ISO |
20 |
6,637,478 |
6,686,768 |
RGD:6480464 |
CTD |
| G |
Fkbp5 |
FK506 binding protein 5 |
|
multiple interactions |
ISO |
20 |
6,637,478 |
6,686,768 |
RGD:6480464 |
CTD |
| G |
Fkbp5 |
FK506 binding protein 5 |
|
increases expression |
EXP |
20 |
6,637,478 |
6,686,768 |
RGD:6480464 |
CTD |
| G |
Fkbp5 |
FK506 binding protein 5 |
|
multiple interactions |
EXP |
20 |
6,637,478 |
6,686,768 |
RGD:6480464 |
CTD |
| G |
Fkbp5 |
FK506 binding protein 5 |
|
multiple interactions |
ISO |
20 |
6,637,478 |
6,686,768 |
RGD:6480464 |
CTD |
| G |
Flot1 |
flotillin 1 |
|
multiple interactions |
ISO |
20 |
3,065,792 |
3,076,166 |
RGD:6480464 |
CTD |
| G |
Fmo1 |
flavin containing monooxygenase 1 |
|
affects expression |
EXP |
13 |
78,503,770 |
78,536,359 |
RGD:6480464 |
CTD |
| G |
Fmo1 |
flavin containing monooxygenase 1 |
|
multiple interactions |
ISO |
13 |
78,503,770 |
78,536,359 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
multiple interactions |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fn1 |
fibronectin 1 |
|
multiple interactions |
EXP |
9 |
70,702,181 |
70,771,155 |
RGD:6480464 |
CTD |
| G |
Fn1 |
fibronectin 1 |
|
decreases expression |
EXP |
9 |
70,702,181 |
70,771,155 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fosl2 |
fos-like antigen 2 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Foxg1 |
forkhead box G1 |
|
decreases expression |
EXP |
6 |
69,217,672 |
69,220,482 |
RGD:6480464 |
CTD |
| G |
Foxg1 |
forkhead box G1 |
|
multiple interactions |
EXP |
6 |
69,217,672 |
69,220,482 |
RGD:6480464 |
CTD |
| G |
Foxo1 |
forkhead box O1 |
|
increases expression |
EXP |
2 |
141,127,345 |
141,203,446 |
RGD:6480464 |
CTD |
| G |
Foxo1 |
forkhead box O1 |
|
increases expression |
EXP |
2 |
141,127,345 |
141,203,446 |
RGD:6480464 |
CTD |
| G |
Foxo1 |
forkhead box O1 |
|
multiple interactions |
EXP |
2 |
141,127,345 |
141,203,446 |
RGD:6480464 |
CTD |
| G |
Foxq1 |
forkhead box Q1 |
|
multiple interactions |
EXP |
17 |
39,332,906 |
39,334,655 |
RGD:6480464 |
CTD |
| G |
Fpr1 |
formyl peptide receptor 1 |
|
increases expression |
ISO |
1 |
56,587,183 |
56,588,390 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
increases expression |
ISO |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
multiple interactions |
ISO |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Fzd2 |
frizzled family receptor 2 |
|
multiple interactions |
ISO |
10 |
91,709,222 |
91,711,132 |
RGD:6480464 |
CTD |
| G |
G6pc |
glucose-6-phosphatase, catalytic subunit |
|
multiple interactions |
EXP |
10 |
90,393,531 |
90,403,485 |
RGD:6480464 |
CTD |
| G |
G6pc |
glucose-6-phosphatase, catalytic subunit |
|
increases expression |
EXP |
10 |
90,393,531 |
90,403,485 |
RGD:6480464 |
CTD |
| G |
G6pc |
glucose-6-phosphatase, catalytic subunit |
|
increases expression |
EXP |
10 |
90,393,531 |
90,403,485 |
RGD:6480464 |
CTD |
| G |
Hao1 |
hydroxyacid oxidase (glycolate oxidase) 1 |
|
multiple interactions |
EXP |
3 |
122,506,916 |
122,564,012 |
RGD:6480464 |
CTD |
| G |
Has2 |
hyaluronan synthase 2 |
|
decreases expression |
ISO |
7 |
93,230,135 |
93,256,139 |
RGD:6480464 |
CTD |
| G |
Hbegf |
heparin-binding EGF-like growth factor |
|
decreases expression |
EXP |
18 |
29,143,567 |
29,153,944 |
RGD:6480464 |
CTD |
| G |
Hdac1 |
histone deacetylase 1 |
|
multiple interactions |
EXP |
5 |
148,672,515 |
148,699,810 |
RGD:6480464 |
CTD |
| G |
Hdac4 |
histone deacetylase 4 |
|
increases expression |
ISO |
9 |
91,147,435 |
91,389,810 |
RGD:6480464 |
CTD |
| G |
Hdc |
histidine decarboxylase |
|
multiple interactions |
EXP |
3 |
114,119,316 |
114,138,107 |
RGD:6480464 |
CTD |
| G |
Hdc |
histidine decarboxylase |
|
multiple interactions |
EXP |
3 |
114,119,316 |
114,138,107 |
RGD:6480464 |
CTD |
| G |
Hdc |
histidine decarboxylase |
|
decreases activity |
EXP |
3 |
114,119,316 |
114,138,107 |
RGD:6480464 |
CTD |
| G |
Hdc |
histidine decarboxylase |
|
decreases expression |
EXP |
3 |
114,119,316 |
114,138,107 |
RGD:6480464 |
CTD |
| G |
Hes1 |
hairy and enhancer of split 1 (Drosophila) |
|
decreases expression |
ISO |
11 |
72,603,482 |
72,605,673 |
RGD:6480464 |
CTD |
| G |
Hibadh |
3-hydroxyisobutyrate dehydrogenase |
|
increases expression |
EXP |
4 |
80,850,300 |
80,948,361 |
RGD:6480464 |
CTD |
| G |
Hk2 |
hexokinase 2 |
|
multiple interactions |
ISO |
4 |
116,925,725 |
116,975,211 |
RGD:6480464 |
CTD |
| G |
Hk2 |
hexokinase 2 |
|
decreases expression |
EXP |
4 |
116,925,725 |
116,975,211 |
RGD:6480464 |
CTD |
| G |
Hmgb2 |
high mobility group box 2 |
|
decreases expression |
EXP |
16 |
36,131,304 |
36,133,878 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
increases expression |
EXP |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) |
|
decreases expression |
ISO |
2 |
51,737,090 |
51,754,583 |
RGD:6480464 |
CTD |
| G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) |
|
increases expression |
EXP |
2 |
51,737,090 |
51,754,583 |
RGD:6480464 |
CTD |
| G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) |
|
increases expression |
EXP |
2 |
193,128,736 |
193,143,106 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox2 |
heme oxygenase (decycling) 2 |
|
multiple interactions |
ISO |
10 |
10,914,157 |
10,929,448 |
RGD:6480464 |
CTD |
| G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
|
multiple interactions |
ISO |
3 |
154,459,863 |
154,482,825 |
RGD:6480464 |
CTD |
| G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
|
increases activity |
ISO |
3 |
154,459,863 |
154,482,825 |
RGD:6480464 |
CTD |
| G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
|
increases expression |
ISO |
3 |
154,459,863 |
154,482,825 |
RGD:6480464 |
CTD |
| G |
Il10rb |
interleukin 10 receptor, beta |
|
multiple interactions |
ISO |
11 |
31,381,317 |
31,397,079 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
ISO |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
EXP |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il12rb2 |
interleukin 12 receptor, beta 2 |
|
decreases expression |
ISO |
4 |
96,929,755 |
96,995,733 |
RGD:6480464 |
CTD |
| G |
Il13 |
interleukin 13 |
|
multiple interactions |
ISO |
10 |
39,093,512 |
39,096,069 |
RGD:6480464 |
CTD |
| G |
Il13 |
interleukin 13 |
|
decreases expression |
ISO |
10 |
39,093,512 |
39,096,069 |
RGD:6480464 |
CTD |
| G |
Il13ra1 |
interleukin 13 receptor, alpha 1 |
|
increases expression |
ISO |
X |
8,758,662 |
8,820,545 |
RGD:6480464 |
CTD |
| G |
Il15 |
interleukin 15 |
|
increases expression |
ISO |
19 |
27,487,268 |
27,498,973 |
RGD:6480464 |
CTD |
| G |
Il15 |
interleukin 15 |
|
decreases expression |
EXP |
19 |
27,487,268 |
27,498,973 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Ins2 |
insulin 2 |
|
multiple interactions |
ISO |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
| G |
Insr |
insulin receptor |
|
multiple interactions |
ISO |
12 |
2,934,967 |
3,087,691 |
RGD:6480464 |
CTD |
| G |
Irs1 |
insulin receptor substrate 1 |
|
multiple interactions |
ISO |
9 |
81,585,251 |
81,638,071 |
RGD:6480464 |
CTD |
| G |
Itgam |
integrin, alpha M |
|
multiple interactions |
ISO |
1 |
187,334,413 |
187,385,583 |
RGD:6480464 |
CTD |
| G |
Itsn1 |
intersectin 1 (SH3 domain protein) |
|
decreases expression |
EXP |
11 |
31,721,528 |
31,901,963 |
RGD:6480464 |
CTD |
| G |
Itsn1 |
intersectin 1 (SH3 domain protein) |
|
multiple interactions |
EXP |
11 |
31,721,528 |
31,901,963 |
RGD:6480464 |
CTD |
| G |
Jag1 |
jagged 1 |
|
multiple interactions |
EXP |
3 |
125,181,063 |
125,216,481 |
RGD:6480464 |
CTD |
| G |
Jam3 |
junctional adhesion molecule 3 |
|
increases expression |
ISO |
8 |
26,697,127 |
26,758,579 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
decreases expression |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Kcna2 |
potassium voltage-gated channel, shaker-related subfamily, member 2 |
|
multiple interactions |
EXP |
2 |
202,560,152 |
202,564,305 |
RGD:6480464 |
CTD |
| G |
Kcna5 |
potassium voltage-gated channel, shaker-related subfamily, member 5 |
|
increases expression |
EXP |
4 |
162,896,283 |
162,898,091 |
RGD:6480464 |
CTD |
| G |
Kcna5 |
potassium voltage-gated channel, shaker-related subfamily, member 5 |
|
multiple interactions |
EXP |
4 |
162,896,283 |
162,898,091 |
RGD:6480464 |
CTD |
| G |
Kcnab1 |
potassium voltage-gated channel, shaker-related subfamily, beta member 1 |
|
decreases expression |
EXP |
2 |
154,837,841 |
155,145,882 |
RGD:6480464 |
CTD |
| G |
Kcnab1 |
potassium voltage-gated channel, shaker-related subfamily, beta member 1 |
|
multiple interactions |
EXP |
2 |
154,837,841 |
155,145,882 |
RGD:6480464 |
CTD |
| G |
Kcnb1 |
potassium voltage gated channel, Shab-related subfamily, member 1 |
|
multiple interactions |
EXP |
3 |
158,250,001 |
158,345,927 |
RGD:6480464 |
CTD |
| G |
Kcnk1 |
potassium channel, subfamily K, member 1 |
|
increases expression |
ISO |
19 |
56,216,600 |
56,255,299 |
RGD:6480464 |
CTD |
| G |
Kcnma1 |
potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
|
multiple interactions |
EXP |
15 |
575,136 |
950,275 |
RGD:6480464 |
CTD |
| G |
Kcnn4 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
|
decreases expression |
EXP |
1 |
79,613,736 |
79,628,887 |
RGD:6480464 |
CTD |
| G |
Kcnn4 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
|
multiple interactions |
EXP |
1 |
79,613,736 |
79,628,887 |
RGD:6480464 |
CTD |
| G |
Kctd12 |
potassium channel tetramerisation domain containing 12 |
|
multiple interactions |
ISO |
15 |
86,986,827 |
86,987,810 |
RGD:6480464 |
CTD |
| G |
Kit |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
|
decreases expression |
ISO |
14 |
34,906,043 |
34,984,819 |
RGD:6480464 |
CTD |
| G |
Kitlg |
KIT ligand |
|
multiple interactions |
ISO |
7 |
37,714,157 |
37,795,722 |
RGD:6480464 |
CTD |
| G |
Mapk4 |
mitogen-activated protein kinase 4 |
|
multiple interactions |
ISO |
18 |
70,707,645 |
70,755,517 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
affects phosphorylation |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
|
multiple interactions |
ISO |
20 |
41,304,058 |
41,310,104 |
RGD:6480464 |
CTD |
| G |
Mbl2 |
mannose-binding lectin (protein C) 2 |
|
decreases expression |
EXP |
1 |
233,978,931 |
233,983,824 |
RGD:6480464 |
CTD |
| G |
Mbl2 |
mannose-binding lectin (protein C) 2 |
|
multiple interactions |
EXP |
1 |
233,978,931 |
233,983,824 |
RGD:6480464 |
CTD |
| G |
Mbnl1 |
muscleblind-like splicing regulator 1 |
|
increases expression |
EXP |
2 |
149,891,873 |
150,004,089 |
RGD:6480464 |
CTD |
| G |
Mbnl1 |
muscleblind-like splicing regulator 1 |
|
multiple interactions |
EXP |
2 |
149,891,873 |
150,004,089 |
RGD:6480464 |
CTD |
| G |
Mc5r |
melanocortin 5 receptor |
|
increases expression |
EXP |
18 |
64,679,384 |
64,680,417 |
RGD:6480464 |
CTD |
| G |
Mc5r |
melanocortin 5 receptor |
|
multiple interactions |
EXP |
18 |
64,679,384 |
64,680,417 |
RGD:6480464 |
CTD |
| G |
Mcam |
melanoma cell adhesion molecule |
|
decreases expression |
EXP |
8 |
47,105,632 |
47,127,936 |
RGD:6480464 |
CTD |
| G |
Mcam |
melanoma cell adhesion molecule |
|
multiple interactions |
EXP |
8 |
47,105,632 |
47,127,936 |
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcoln2 |
mucolipin 2 |
|
decreases expression |
EXP |
2 |
244,323,411 |
244,385,583 |
RGD:6480464 |
CTD |
| G |
Mcoln2 |
mucolipin 2 |
|
multiple interactions |
EXP |
2 |
244,323,411 |
244,385,583 |
RGD:6480464 |
CTD |
| G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
|
multiple interactions |
EXP |
8 |
91,839,845 |
91,955,917 |
RGD:6480464 |
CTD |
| G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
|
decreases expression |
EXP |
8 |
91,839,845 |
91,955,917 |
RGD:6480464 |
CTD |
| G |
Med1 |
mediator complex subunit 1 |
|
affects response to substance |
ISO |
10 |
86,917,525 |
86,959,080 |
RGD:6480464 |
CTD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
multiple interactions |
ISO |
8 |
4,333,773 |
4,354,284 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
|
increases expression |
EXP |
MT |
5,323 |
6,867 |
RGD:6480464 |
CTD |
| G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
|
increases expression |
EXP |
MT |
7,006 |
7,689 |
RGD:6480464 |
CTD |
| G |
Mt-co3 |
mitochondrially encoded cytochrome c oxidase III |
|
increases expression |
EXP |
MT |
8,599 |
9,382 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
multiple interactions |
EXP |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
increases expression |
EXP |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
multiple interactions |
EXP |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Nelfa |
negative elongation factor complex member A |
|
increases expression |
ISO |
14 |
82,502,840 |
82,526,916 |
RGD:6480464 |
CTD |
| G |
Noc3l |
nucleolar complex associated 3 homolog (S. cerevisiae) |
|
increases expression |
ISO |
1 |
243,108,787 |
243,137,316 |
RGD:6480464 |
CTD |
| G |
Nol3 |
nucleolar protein 3 (apoptosis repressor with CARD domain) |
|
multiple interactions |
EXP |
19 |
35,094,345 |
35,096,012 |
RGD:6480464 |
CTD |
| G |
Nol3 |
nucleolar protein 3 (apoptosis repressor with CARD domain) |
|
increases expression |
EXP |
19 |
35,094,345 |
35,096,012 |
RGD:6480464 |
CTD |
| G |
Nop16 |
NOP16 nucleolar protein |
|
decreases expression |
ISO |
17 |
16,084,950 |
16,089,867 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
decreases expression |
ISO |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
multiple interactions |
ISO |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
affects expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
affects response to substance |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
affects localization |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases expression |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases activity |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases expression |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
increases expression |
ISO |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
|
multiple interactions |
ISO |
7 |
140,012,807 |
140,020,590 |
RGD:6480464 |
CTD |
| G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
|
affects localization |
EXP |
7 |
140,012,807 |
140,020,590 |
RGD:6480464 |
CTD |
| G |
Nr6a1 |
nuclear receptor subfamily 6, group A, member 1 |
|
increases expression |
ISO |
3 |
18,533,072 |
18,564,668 |
RGD:6480464 |
CTD |
| G |
Nrxn2 |
neurexin 2 |
|
multiple interactions |
EXP |
1 |
209,211,740 |
209,318,064 |
RGD:6480464 |
CTD |
| G |
Nrxn2 |
neurexin 2 |
|
increases expression |
EXP |
1 |
209,211,740 |
209,318,064 |
RGD:6480464 |
CTD |
| G |
Nudt21 |
nudix (nucleoside diphosphate linked moiety X)-type motif 21 |
|
increases expression |
ISO |
19 |
11,412,732 |
11,428,838 |
RGD:6480464 |
CTD |
| G |
Odc1 |
ornithine decarboxylase 1 |
|
decreases expression |
EXP |
6 |
41,309,211 |
41,315,796 |
RGD:6480464 |
CTD |
| G |
Odc1 |
ornithine decarboxylase 1 |
|
increases expression |
EXP |
6 |
41,309,211 |
41,315,796 |
RGD:6480464 |
CTD |
| G |
Ogn |
osteoglycin |
|
multiple interactions |
ISO |
17 |
20,987,029 |
21,007,525 |
RGD:6480464 |
CTD |
| G |
Olfm4 |
olfactomedin 4 |
|
increases expression |
ISO |
15 |
61,267,802 |
61,290,288 |
RGD:6480464 |
CTD |
| G |
Omd |
osteomodulin |
|
multiple interactions |
ISO |
17 |
21,015,178 |
21,023,126 |
RGD:6480464 |
CTD |
| G |
Onecut1 |
one cut homeobox 1 |
|
increases expression |
EXP |
8 |
79,644,305 |
79,672,772 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
multiple interactions |
ISO |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Por |
P450 (cytochrome) oxidoreductase |
|
increases expression |
EXP |
12 |
22,078,629 |
22,097,301 |
RGD:6480464 |
CTD |
| G |
Pou5f1 |
POU class 5 homeobox 1 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ppard |
peroxisome proliferator-activated receptor delta |
|
increases expression |
ISO |
20 |
6,479,108 |
6,544,255 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
decreases expression |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
EXP |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases expression |
EXP |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
EXP |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases expression |
ISO |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
decreases expression |
EXP |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
multiple interactions |
EXP |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases expression |
EXP |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
multiple interactions |
EXP |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
| G |
Ppat |
phosphoribosyl pyrophosphate amidotransferase |
|
decreases expression |
ISO |
14 |
33,509,364 |
33,543,743 |
RGD:6480464 |
CTD |
| G |
Ppib |
peptidylprolyl isomerase B |
|
increases expression |
EXP |
8 |
70,343,463 |
70,349,320 |
RGD:6480464 |
CTD |
| G |
Ppib |
peptidylprolyl isomerase B |
|
multiple interactions |
EXP |
8 |
70,343,463 |
70,349,320 |
RGD:6480464 |
CTD |
| G |
Ppp2r5a |
protein phosphatase 2, regulatory subunit B', alpha |
|
decreases expression |
ISO |
13 |
107,413,761 |
107,458,156 |
RGD:6480464 |
CTD |
| G |
Ppp3cb |
protein phosphatase 3, catalytic subunit, beta isozyme |
|
decreases expression |
ISO |
15 |
3,986,290 |
4,030,352 |
RGD:6480464 |
CTD |
| G |
Prim2 |
primase, DNA, polypeptide 2 |
|
decreases expression |
EXP |
9 |
32,206,274 |
32,424,970 |
RGD:6480464 |
CTD |
| G |
Prim2 |
primase, DNA, polypeptide 2 |
|
multiple interactions |
EXP |
9 |
32,206,274 |
32,424,970 |
RGD:6480464 |
CTD |
| G |
Prkacb |
protein kinase, cAMP dependent, catalytic, beta |
|
decreases phosphorylation |
EXP |
2 |
244,949,303 |
245,035,266 |
RGD:6480464 |
CTD |
| G |
Rasa3 |
RAS p21 protein activator 3 |
|
multiple interactions |
ISO |
16 |
80,710,463 |
80,824,220 |
RGD:6480464 |
CTD |
| G |
Rora |
RAR-related orphan receptor A |
|
multiple interactions |
ISO |
8 |
73,052,282 |
73,817,764 |
RGD:6480464 |
CTD |
| G |
RT1-Ba |
RT1 class II, locus Ba |
|
increases expression |
ISO |
20 |
4,697,971 |
4,702,564 |
RGD:6480464 |
CTD |
| G |
RT1-Bb |
RT1 class II, locus Bb |
|
affects expression |
ISO |
20 |
4,730,559 |
4,736,201 |
RGD:6480464 |
CTD |
| G |
RT1-DMb |
RT1 class II, locus DMb |
|
decreases expression |
ISO |
20 |
4,829,535 |
4,836,772 |
RGD:6480464 |
CTD |
| G |
Rxra |
retinoid X receptor alpha |
|
increases expression |
ISO |
3 |
6,605,782 |
6,689,224 |
RGD:6480464 |
CTD |
| G |
Ryk |
receptor-like tyrosine kinase |
|
multiple interactions |
EXP |
8 |
107,822,823 |
107,894,331 |
RGD:6480464 |
CTD |
| G |
S100a8 |
S100 calcium binding protein A8 |
|
increases expression |
ISO |
2 |
182,961,994 |
182,962,513 |
RGD:6480464 |
CTD |
| G |
S100a9 |
S100 calcium binding protein A9 |
|
increases expression |
ISO |
2 |
182,985,466 |
182,988,147 |
RGD:6480464 |
CTD |
| G |
S100a9 |
S100 calcium binding protein A9 |
|
decreases expression |
EXP |
2 |
182,985,466 |
182,988,147 |
RGD:6480464 |
CTD |
| G |
S100a9 |
S100 calcium binding protein A9 |
|
increases expression |
EXP |
2 |
182,985,466 |
182,988,147 |
RGD:6480464 |
CTD |
| G |
S100a9 |
S100 calcium binding protein A9 |
|
multiple interactions |
EXP |
2 |
182,985,466 |
182,988,147 |
RGD:6480464 |
CTD |
| G |
Scarb1 |
scavenger receptor class B, member 1 |
|
decreases expression |
EXP |
12 |
32,390,183 |
32,457,661 |
RGD:6480464 |
CTD |
| G |
Scd |
stearoyl-CoA desaturase (delta-9-desaturase) |
|
decreases expression |
EXP |
1 |
249,358,105 |
249,371,164 |
RGD:6480464 |
CTD |
| G |
Scd |
stearoyl-CoA desaturase (delta-9-desaturase) |
|
affects expression |
EXP |
1 |
249,358,105 |
249,371,164 |
RGD:6480464 |
CTD |
| G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
|
multiple interactions |
ISO |
1 |
249,458,860 |
249,471,460 |
RGD:6480464 |
CTD |
| G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
|
decreases expression |
EXP |
1 |
249,458,860 |
249,471,460 |
RGD:6480464 |
CTD |
| G |
Scel |
sciellin |
|
increases expression |
ISO |
15 |
87,547,770 |
87,678,387 |
RGD:6480464 |
CTD |
| G |
Scn8a |
sodium channel, voltage gated, type VIII, alpha subunit |
|
decreases expression |
EXP |
7 |
139,686,180 |
139,794,282 |
RGD:6480464 |
CTD |
| G |
Scn8a |
sodium channel, voltage gated, type VIII, alpha subunit |
|
multiple interactions |
EXP |
7 |
139,686,180 |
139,794,282 |
RGD:6480464 |
CTD |
| G |
Scnn1a |
sodium channel, nonvoltage-gated 1 alpha |
|
increases expression |
ISO |
4 |
161,445,936 |
161,469,267 |
RGD:6480464 |
CTD |
| G |
Scnn1b |
sodium channel, nonvoltage-gated 1, beta |
|
multiple interactions |
ISO |
1 |
180,682,622 |
180,748,068 |
RGD:6480464 |
CTD |
| G |
Scnn1b |
sodium channel, nonvoltage-gated 1, beta |
|
increases expression |
ISO |
1 |
180,682,622 |
180,748,068 |
RGD:6480464 |
CTD |
| G |
Scnn1b |
sodium channel, nonvoltage-gated 1, beta |
|
increases expression |
ISO |
1 |
180,682,622 |
180,748,068 |
RGD:6480464 |
CTD |
| G |
Scnn1b |
sodium channel, nonvoltage-gated 1, beta |
|
increases expression |
EXP |
1 |
180,682,622 |
180,748,068 |
RGD:6480464 |
CTD |
| G |
Scnn1g |
sodium channel, nonvoltage-gated 1, gamma |
|
multiple interactions |
ISO |
1 |
180,555,660 |
180,589,534 |
RGD:6480464 |
CTD |
| G |
Scnn1g |
sodium channel, nonvoltage-gated 1, gamma |
|
increases expression |
ISO |
1 |
180,555,660 |
180,589,534 |
RGD:6480464 |
CTD |
| G |
Scnn1g |
sodium channel, nonvoltage-gated 1, gamma |
|
increases expression |
EXP |
1 |
180,555,660 |
180,589,534 |
RGD:6480464 |
CTD |
| G |
Sdc1 |
syndecan 1 |
|
decreases expression |
ISO |
6 |
32,253,352 |
32,275,812 |
RGD:6480464 |
CTD |
| G |
Sdc2 |
syndecan 2 |
|
multiple interactions |
ISO |
7 |
68,290,558 |
68,405,183 |
RGD:6480464 |
CTD |
| G |
Sdc4 |
syndecan 4 |
|
increases expression |
EXP |
3 |
155,446,138 |
155,464,825 |
RGD:6480464 |
CTD |
| G |
Sdc4 |
syndecan 4 |
|
multiple interactions |
EXP |
3 |
155,446,138 |
155,464,825 |
RGD:6480464 |
CTD |
| G |
Sdcbp |
syndecan binding protein |
|
increases expression |
ISO |
5 |
19,822,440 |
19,849,223 |
RGD:6480464 |
CTD |
| G |
Sephs2 |
selenophosphate synthetase 2 |
|
increases expression |
EXP |
1 |
186,535,717 |
186,538,035 |
RGD:6480464 |
CTD |
| G |
Sephs2 |
selenophosphate synthetase 2 |
|
multiple interactions |
EXP |
1 |
186,535,717 |
186,538,035 |
RGD:6480464 |
CTD |
| G |
Sepp1 |
selenoprotein P, plasma, 1 |
|
increases expression |
EXP |
2 |
52,451,883 |
52,462,263 |
RGD:6480464 |
CTD |
| G |
Sepp1 |
selenoprotein P, plasma, 1 |
|
increases secretion |
EXP |
2 |
52,451,883 |
52,462,263 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
increases expression |
EXP |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Slc7a6 |
solute carrier family 7 (amino acid transporter light chain, y+L system), member 6 |
|
increases expression |
EXP |
19 |
36,032,750 |
36,049,384 |
RGD:6480464 |
CTD |
| G |
Slc7a6 |
solute carrier family 7 (amino acid transporter light chain, y+L system), member 6 |
|
multiple interactions |
EXP |
19 |
36,032,750 |
36,049,384 |
RGD:6480464 |
CTD |
| G |
Slc9a3 |
solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 |
|
increases expression |
EXP |
1 |
29,930,908 |
29,973,686 |
RGD:6480464 |
CTD |
| G |
Slc9a3 |
solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 |
|
increases expression |
ISO |
1 |
29,930,908 |
29,973,686 |
RGD:6480464 |
CTD |
| G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1b3 |
solute carrier organic anion transporter family, member 1b3 |
|
decreases expression |
ISO |
4 |
179,045,586 |
179,118,680 |
RGD:6480464 |
CTD |
| G |
Slco1b3 |
solute carrier organic anion transporter family, member 1b3 |
|
decreases expression |
EXP |
4 |
179,045,586 |
179,118,680 |
RGD:6480464 |
CTD |
| G |
Slco1b3 |
solute carrier organic anion transporter family, member 1b3 |
|
multiple interactions |
EXP |
4 |
179,045,586 |
179,118,680 |
RGD:6480464 |
CTD |
| G |
Slco2a1 |
solute carrier organic anion transporter family, member 2a1 |
|
decreases expression |
ISO |
8 |
108,012,829 |
108,098,561 |
RGD:6480464 |
CTD |
| G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
|
decreases expression |
ISO |
1 |
156,992,492 |
157,028,887 |
RGD:6480464 |
CTD |
| G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
|
multiple interactions |
ISO |
9 |
96,042,701 |
96,092,537 |
RGD:6480464 |
CTD |
| G |
Smad3 |
SMAD family member 3 |
|
affects expression |
ISO |
8 |
67,803,909 |
67,952,056 |
RGD:6480464 |
CTD |
| G |
Smoc2 |
SPARC related modular calcium binding 2 |
|
decreases expression |
EXP |
1 |
53,165,792 |
53,295,145 |
RGD:6480464 |
CTD |
| G |
Smoc2 |
SPARC related modular calcium binding 2 |
|
multiple interactions |
EXP |
1 |
53,165,792 |
53,295,145 |
RGD:6480464 |
CTD |
| G |
Socs1 |
suppressor of cytokine signaling 1 |
|
increases expression |
ISO |
10 |
4,819,971 |
4,820,609 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
ISO |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod3 |
superoxide dismutase 3, extracellular |
|
multiple interactions |
ISO |
14 |
63,381,447 |
63,387,180 |
RGD:6480464 |
CTD |
| G |
Sost |
sclerostin |
|
multiple interactions |
ISO |
10 |
91,023,712 |
91,026,759 |
RGD:6480464 |
CTD |
| G |
Sox11 |
SRY (sex determining region Y)-box 11 |
|
decreases expression |
EXP |
6 |
45,141,366 |
45,143,387 |
RGD:6480464 |
CTD |
| G |
Tjap1 |
tight junction associated protein 1 |
|
decreases expression |
EXP |
9 |
10,264,023 |
10,288,320 |
RGD:6480464 |
CTD |
| G |
Tjap1 |
tight junction associated protein 1 |
|
multiple interactions |
EXP |
9 |
10,264,023 |
10,288,320 |
RGD:6480464 |
CTD |
| G |
Tle4 |
transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) |
|
decreases expression |
ISO |
1 |
217,636,135 |
217,770,594 |
RGD:6480464 |
CTD |
| G |
Tlr3 |
toll-like receptor 3 |
|
decreases expression |
ISO |
16 |
50,112,910 |
50,126,371 |
RGD:6480464 |
CTD |
| G |
Tmc5 |
transmembrane channel-like 5 |
|
multiple interactions |
ISO |
1 |
176,854,487 |
176,865,156 |
RGD:6480464 |
CTD |
| G |
Tnc |
tenascin C |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases activity |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Ugt2a1 |
UDP glucuronosyltransferase 2 family, polypeptide A1 |
|
affects expression |
EXP |
14 |
22,047,612 |
22,071,582 |
RGD:6480464 |
CTD |
| G |
Ugt2b17 |
UDP glucuronosyltransferase 2 family, polypeptide B17 |
|
affects expression |
EXP |
14 |
22,639,182 |
22,650,931 |
RGD:6480464 |
CTD |
| G |
Ugt2b17 |
UDP glucuronosyltransferase 2 family, polypeptide B17 |
|
increases expression |
EXP |
14 |
22,639,182 |
22,650,931 |
RGD:6480464 |
CTD |
| G |
Usp3 |
ubiquitin specific peptidase 3 |
|
increases expression |
EXP |
8 |
70,821,429 |
70,897,119 |
RGD:6480464 |
CTD |
| G |
Vangl1 |
VANGL planar cell polarity protein 1 |
|
decreases expression |
EXP |
2 |
197,248,680 |
197,296,021 |
RGD:6480464 |
CTD |
| G |
Vangl1 |
VANGL planar cell polarity protein 1 |
|
multiple interactions |
EXP |
2 |
197,248,680 |
197,296,021 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
decreases expression |
EXP |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
multiple interactions |
EXP |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
decreases expression |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
EXP |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vcan |
versican |
|
multiple interactions |
ISO |
2 |
19,712,629 |
19,801,443 |
RGD:6480464 |
CTD |
| G |
Vdr |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
increases expression |
ISO |
7 |
136,567,614 |
136,617,280 |
RGD:6480464 |
CTD |
| G |
Vdr |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
multiple interactions |
ISO |
7 |
136,567,614 |
136,617,280 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases secretion |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Wfdc1 |
WAP four-disulfide core domain 1 |
|
decreases expression |
EXP |
19 |
49,924,440 |
49,943,113 |
RGD:6480464 |
CTD |
| G |
Wfs1 |
Wolfram syndrome 1 (wolframin) |
|
increases expression |
ISO |
14 |
79,379,680 |
79,404,003 |
RGD:6480464 |
CTD |
| G |
Wif1 |
Wnt inhibitory factor 1 |
|
multiple interactions |
ISO |
7 |
60,330,517 |
60,400,697 |
RGD:6480464 |
CTD |
| G |
Wisp2 |
WNT1 inducible signaling pathway protein 2 |
|
multiple interactions |
ISO |
3 |
154,748,977 |
154,760,324 |
RGD:6480464 |
CTD |
| G |
Wnk4 |
WNK lysine deficient protein kinase 4 |
|
increases expression |
ISO |
10 |
90,289,273 |
90,306,225 |
RGD:6480464 |
CTD |
| G |
Wnt3a |
wingless-type MMTV integration site family, member 3A |
|
multiple interactions |
ISO |
10 |
45,553,682 |
45,594,983 |
RGD:6480464 |
CTD |
| G |
Wnt4 |
wingless-type MMTV integration site family, member 4 |
|
decreases expression |
EXP |
5 |
156,064,371 |
156,083,198 |
RGD:6480464 |
CTD |
| G |
Wnt4 |
wingless-type MMTV integration site family, member 4 |
|
multiple interactions |
EXP |
5 |
156,064,371 |
156,083,198 |
RGD:6480464 |
CTD |
Term paths to the root
|